AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05063513 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Experimental arm will undergo mobilisation with CY 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
Study NCT05063513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
Study NCT03459560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyPill
Description: After the baseline enrollment and excluding non-eligible participants, we randomized villages to Polypill and control arms. Follow-ups are scheduled for 1, 3, and 6 months after the initial enrollment in the Polypill arm and every six months thereafter. For the minimal care arm, the follow-ups are arranged every six months.
Study NCT01967966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Single oral dose
Study NCT01967966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Single IV dose
Study NCT01417156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: 150 mg bid
Study NCT01417156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidoneone
Description: Existing treatment
Study NCT01580605 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment
Study NCT03320902 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sudden death counselling
Description: The Sudden Death Counselling with included relatives at 1 month (+/-15 days) after the eventafter the event will be at the Europeen Georges Pompidou hospital in Paris.~The purpose of this Sudden Death Counselling is to provide to family members of sudden death victims information, support, referral and follow-up services relating to sudden death and their grief, if needed.~The bereaved people will tell their experience. The Sudden Death Counselling would help them to integrate life's losses by companioning them.~Cardiologist and psychologists will be present to listen to their pain and try to bring comfort by answering to their questionings.
Study NCT01198769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix TM
Description: Oral, 2 doses
Study NCT03175705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HCC antigens-specific CD8+ T lymphocytes
Description: Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10\^7/m2 Loading Dose 2: 6x10\^7/m2 Loading Dose 3: 9x10\^7/m2 The doses are calculated according to the actual number of GPC3/NY-ESO-1/AFP specific cytotoxic lymphocytes (CTLs)
Study NCT03175705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 will be given at a dose of 25000 IU/kg/day for 5-14 days.
Study NCT03175705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 5 mg single oral dose
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 25 mg single oral dose
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 75 mg single oral dose
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 150 mg single oral dose
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 300 mg single oral dose
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 600 mg single oral dose
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 300 mg single oral dose (females)
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 100 mg multiple oral dose
Study NCT01509729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroscopic surgery
Description: A randomized group of patients was given small patches with active 5% lidocaine.
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 300 mg multiple oral dose
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 100 mg BID multiple oral dose
Study NCT01521832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 100 mg BID multiple oral dose (females)
Study NCT00917748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL(XRP6976) + MODAFINIL
Description: arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
Study NCT00917748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DOCETAXEL(XRP6976) + MODAFINIL
Description: arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
Study NCT00917748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
Study NCT00917748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Modafinil
Description: Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
Study NCT01555632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Description: Given PO
Study NCT01555632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT03335475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Lifestyle Intervention
Description: Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
Study NCT03335475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Monitoring
Description: A physical activity monitor (Fitbit) will be provided to both groups.
Study NCT03335475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Monitoring
Description: A physical activity monitor (Fitbit) will be provided to both groups.
Study NCT01030289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real tDCS
Description: transcranial direct current stimulation
Study NCT01030289 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: transcranial direct current stimulation
Study NCT00459277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
Study NCT00459277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
Study NCT00658723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Pad
Description: Fibrin Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
Study NCT00658723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL™
Description: Absorbable hemostat
Study NCT03792399 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: feedback counseling
Description: Professoinal CGM in combination with diet and exercise record is used as teaching material to help patient realize their blood glucose pattern and to modify their behavior after counseling feedback.
Study NCT03792399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: feedback counseling
Description: Professoinal CGM in combination with diet and exercise record is used as teaching material to help patient realize their blood glucose pattern and to modify their behavior after counseling feedback.
Study NCT01405820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab SC
Description: natalizumab for Subcutaneous Injection
Study NCT00047073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Phase 1: Initial dose 6mg on day 1 and then 2mg each day for 5-7 days before surgery. No dosing during surgery recovery. After recorvery 6mg loading dose on day 1 then 2mg each day. Cycle is every 4 weeks.~Dose escalation: Level 2: 15mg load/5mg/day, Level 3: 30mg load/10mg/day, Level 4: 45mg load/15mg/day.~Phase 2: Will utilize dose established in phase I. Dosing schedule will remain the same.
Study NCT00047073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical resection.
Study NCT02089672 — intervention group
Intervention type: DEVICE
Intervention: Catheter ablation
Description: This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
Study NCT00047073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Corticosteroids should be used in smallest dose to control symptoms of cerebral edema and mass effect.~Anti-seizure medications should be used as indicated. Febrile neutropenia may be managed according to local institution's infectious disease guidelines.~If neurosurgical management is required for reasons not due to tumor progression, these procedures must be documented.
Study NCT04016129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
Description: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
Study NCT03774628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chengdu Kanghua (one booster shot)
Description: A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0
Study NCT03774628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chengdu Kanghua (two booster shots)
Description: A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3
Study NCT02504073 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04236791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
Study NCT01405820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Placebo
Description: Intravenous placebo to natalizumab
Study NCT01405820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Placebo
Description: Subcutaneous placebo to natalizumab
Study NCT02152020 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Study NCT04383704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Dietary pattern ( Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND))
Description: A new brain-protection pattern that has been designed after the Mediterranean and DASH diet to improve some of their dietary factors to have the highest impact on brain health and cognitive performance.
Study NCT04383704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New Dietary pattern ( Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND))
Description: A new brain-protection pattern that has been designed after the Mediterranean and DASH diet to improve some of their dietary factors to have the highest impact on brain health and cognitive performance.
Study NCT02370706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIM447
Description: pan-pim inhibitor
Study NCT06018675 — intervention group
Intervention type: OTHER
Intervention: kinesiotherapy
Description: Group 1: Kinesiotherapy Group 2: Dry needling Group 3: lidocain injection
Study NCT04236791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
Study NCT02676479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine Lavage Group
Description: The PI places the Lavage Catheter per instructions for use~* Use of a tenaculum or cervical stitch is required~* Use of saline to wash the cervix is required~* Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix.
Study NCT03274843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity of everyday life
Description: Kitchen workshop
Study NCT01815164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotherapy
Description: Gut-directed hypnotherapy administered by an experienced hypnotherapist.
Study NCT01815164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Educational intervention vith education regarding Irritabel bowel Syndrome.
Study NCT03295188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plasmalogen
Description: Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.
Study NCT03295188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Group takes two placebo capsules per day for 12 weeks.
Study NCT02370706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: JAK1/JAK2 inhibitor
Study NCT04492176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser（ACUPULSE,Lumenis）
Description: gradually withdrawn from inside to outside of vaginal. with Acupulse Femtouch mode therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%) ,once a month for a total of 3 times
Study NCT03376789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYL-1501D product using manufacture process V
Description: MYL-1501D product using manufacture process V
Study NCT04323852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery
Study NCT04323852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02499874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: oral Efavirenz 400mg
Study NCT02499874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir /emtricitabine
Description: tenofovir 245 mg/emtricitabine 200mg
Study NCT02499874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir/lamivudine
Description: tenofovir 245mg/lamivudine 300mg
Study NCT02499874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine/zidovudine
Description: lamivudine 300mg/zidovudine 600mg
Study NCT00487162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensive glycemic control
Description: intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
Study NCT00487162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional glycemic control
Description: Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
Study NCT03376789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYL-1501D product using manufacture process VI
Description: MYL-1501D product using manufacture process VI
Study NCT01050933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 ppm carbon monoxide
Description: 250 ppm of inhaled carbon monoxide over one hour
Study NCT01888172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers Online Program
Description: Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.
Study NCT01888172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips ActiveLink
Description: Provision of a key-chain sized physical activity monitor that interfaces with the Weight Watchers website to promote exercise and give feedback on progress towards exercise goals.
Study NCT01888172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eating and Activity Newsletter
Description: General information on healthy eating and physical activity habits and the medical consequences of overweight/obesity and weight loss.
Study NCT01182051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT or relaxation training
Description: 8 weeks of CBT or relaxation training.
Study NCT01182051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT or relaxation training
Description: 8 weeks of CBT or relaxation training.
Study NCT03859479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
Study NCT03859479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hot snare polypectomy
Description: After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
Study NCT00562172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Once daily in the morning
Study NCT00562172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Once daily in the morning
Study NCT00562172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 1000 mg/day
Study NCT00562172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: At least 1000 mg/day
Study NCT01487122 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Continuous microwave
Description: Continuous microwave through a great circular electrode, 15 cm from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
Study NCT01487122 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed microwaves
Description: Pulsed microwaves through a great circular electrode, 15 cm away from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
Study NCT01487122 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham microwaves
Description: Unplugged microwave generator, great circular electrode, 15 cm away from the neck, 20 minutes, 15 sessions in 3 weeks